Tardive dyskinesia remains a major public health problem in psychiatry. No proven safe and effective treatment has emerged for this condition and at present all marketed antipsychotic drugs appear capable of producing this adverse effect. Therefore, identification of risk factors and the development of strategies for prevention remain major goals. Knowledge regarding factors which might increase the risk for TD is largely based on cross- sectional prevalence surveys and retrospective data collection on important diagnostic, illness and treatment history characteristics. The continuation of the present prospective study would provide a unique opportunity to further develop our prospectively collected database on the incidence and course of tardive dyskinesia as well as factors influencing both of these. To date 955 patients have entered the study including 70 schizophrenic or schizophreniform patients with no prior exposure to neuroleptics at study entry and 135 patients receiving different controlled dosage ranges of fluphenazine decanoate. The median length of total previous neuroleptic exposure at study entry (for those who have been treated) is 12 months, therefore, patients who are being followed from the early part of their treatment course. Sixty-three patients with a documented history of severe parkinsonian side effects to neuroleptic medications are also being followed. The design of the study calls for patients to be evaluated every 3 months with the Simpson Dyskinesia Scale, the Simpson-Angus Scale and the BPRS. Patients with questionable signs of TD are seen monthly. Those developing presumptive TD are evaluated neuromedically, videotaped and seen every 2 weeks, with discontinuation of neuroleptic medication whenever possible. To date 160 cases of presumptive TD have developed and a major focus of the project at present is to investigate TD outcome and to evaluate the effect of prospectively assessed variables (both prior to and subsequent to the development of tardive dyskinesia) on its long-term course.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37MH032369-12
Application #
3486475
Study Section
Treatment Development and Assessment Research Review Committee (TDA)
Project Start
1979-03-01
Project End
1993-03-31
Budget Start
1990-06-01
Budget End
1991-03-31
Support Year
12
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Long Island Jewish Medical Center
Department
Type
DUNS #
City
New Hyde Park
State
NY
Country
United States
Zip Code
11040
Woerner, Margaret G; Correll, Christoph U; Alvir, Jose Ma J et al. (2011) Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. Neuropsychopharmacology 36:1738-46
Correll, Christoph U; Leucht, Stefan; Kane, John M (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:414-25
Kane, J M (1999) Management strategies for the treatment of schizophrenia. J Clin Psychiatry 60 Suppl 12:13-7
Kane, J M (1999) Tardive dyskinesia in affective disorders. J Clin Psychiatry 60 Suppl 5:43-7;discussion 48-9
Kane, J M (1999) Pharmacologic treatment of schizophrenia. Biol Psychiatry 46:1396-408
Miller, C H; Mohr, F; Umbricht, D et al. (1998) The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 59:69-75
Woerner, M G; Alvir, J M; Saltz, B L et al. (1998) Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 155:1521-8
Chakos, M H; Alvir, J M; Woerner, M G et al. (1996) Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 53:313-9
Umbricht, D; Kane, J M (1996) Medical complications of new antipsychotic drugs. Schizophr Bull 22:475-83
Woerner, M G; Alvir, J M; Kane, J M et al. (1995) Neuroleptic treatment of elderly patients. Psychopharmacol Bull 31:333-7

Showing the most recent 10 out of 26 publications